$STAB News
Last published 2y ago
- 2y agoSYTHTCRHOURFUBO+7CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICAPR NewswireAnthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list...
- 3y agoSTABStatera Biopharma Signs Letter of Intent for Merger with Worksite LabsGlobeNewswireFORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies
- 4y agoSTABStatera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing DelinquencyACCESS NewswireFORT COLLINS, CO / ACCESSWIRE / September 9, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, toda
- 4y agoNDAQSTABNasdaq Resumes Trading in Statera Biopharma, Inc.GlobeNewswireNEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading resumed in Statera Biopharma, Inc. (NASDAQ:STAB) today, August 26, 2022 at 7:10 a.m. Eastern Time. Trading in the company's stock was halted on A
- 4y agoSTABStatera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from NasdaqACCESS NewswireFORT COLLINS, CO / ACCESSWIRE / August 25, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today
- 4y agoNDAQSTABNasdaq Halts Statera Biopharma, Inc.GlobeNewswireNEW YORK, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading was halted today in Statera Biopharma, Inc. (NASDAQ:STAB) at 11:01:52 A.M. Eastern Time for "additional information requested" from the company a
- 4y agoSTABStatera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting FirmGlobeNewswireFORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis,
- 4y agoSTABStatera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q FilingGlobeNewswireFORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (NASDAQ:STAB) (the "Company"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company r
- 4y agoSTABStatera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY ProductsGlobeNewswireFORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (NASDAQ:STAB) (the "Company"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Comp
- 4y agoACCDARVLBRQSDUO+1Thinking about buying stock in Fangdd Network Group, Statera Biopharma, Borqs Technologies, Accolade, or Arrival?PR NewswireNEW YORK, April 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DUO, STAB, BRQS, ACCD, and ARVL.
- 4y agoBLNDBRQSCRXTNOK+1Thinking about buying stock in Statera Biopharma, Nokia, Borqs Technologies, Clarus Therapeutics, or Blend Labs?PR NewswireNEW YORK, April 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAB, NOK, BRQS, CRXT, and BLND.
- 4y agoSTABStatera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K FilingGlobeNewswireFORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (NASDAQ:STAB) (the "Company"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company
- 4y agoSTABStatera Biopharma, Inc. Files Form 12b-25GlobeNewswireFORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom
- 4y agoSTABStatera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022GlobeNewswireLive Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immun
- 4y agoSTABStatera Biopharma Announces Closing of $5.7 Million Underwritten Public OfferingGlobeNewswireFORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom
- 4y agoSTABStatera Biopharma Announces Pricing of $5.7 Million Underwritten Public OfferingGlobeNewswireFORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom
- 4y agoSTABCORRECTION -- Statera Biopharma Announces Proposed Underwritten Public OfferingGlobeNewswireFORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom
- 4y agoSTABStatera Biopharma Announces Proposed Underwritten Public OfferingGlobeNewswireFORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom
- 4y agoSTABStatera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021GlobeNewswireFORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom
- 4y agoSTABStatera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 PlatformGlobeNewswireIn collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200 FORT COLLINS, Colo., March 07, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a lea
- 4y agoSTABStatera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19GlobeNewswireFORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to
- 4y agoSTABStatera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year '21GlobeNewswireFORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and home
- 4y agoSTABStatera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn's DiseaseGlobeNewswireSTAT-201 is being developed as a novel, immune-modulation therapy for treating Crohn's Disease Phase 3 trial expected to begin in second quarter 2022 FORT COLLINS, Colo., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a
- 4y agoSTABStatera Biopharma Announces Closing of $2.0 Million Registered Direct OfferingGlobeNewswireFORT COLLINS, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and home
- 4y agoSTABStatera Biopharma Announces Pricing of $2.0 Million Registered Direct OfferingGlobeNewswireFORT COLLINS, Colo., Feb. 06, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and home
- 4y agoSTABStatera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn's DiseaseGlobeNewswireFORT COLLINS, Colo., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to
- 4y agoSTABStatera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVIDGlobeNewswireInitial Study to Evaluate Pharmacokinetics, Biomarkers and Safety of STAT-205 Targeting Preliminary Data 2022 FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (NASDAQ:STAB), a leading biopharmaceutical company creatin
- 4y agoSTABStatera Biopharma Announces FDA Lifts Clinical Hold on EntolimodGlobeNewswireFORT COLLINS, Colo., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the U.S.
- 4y agoSTABStatera Biopharma Provides Third Quarter 2021 Financial and Corporate UpdateGlobeNewswireFORT COLLINS, Co., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today reported important corpora
- 5y agoSTABStatera Biopharma, Inc. to Report Third Quarter 2021 Financial ResultsGlobeNewswireFORT COLLINS, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Compa
- 5y agoSTABStatera Biopharma Honors Pancreatic Cancer Awareness MonthGlobeNewswireFORT COLLINS, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced its support fo
- 5y agoSTABStatera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-19GlobeNewswireResearchers at Loma Linda University Health to Evaluate Pharmacokinetics, Biomarkers and Safety of STAT-205 FORT COLLINS, Colo., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating ne
- 5y agoSTABStatera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma ConferenceGlobeNewswireFORT COLLINS, Colo., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Compa
- 5y agoSTABStatera Biopharma Announces CEO Mike Handley to Speak During Virtual B & T Cell-Mediated Autoimmune Disease Drug Development SummitGlobeNewswireFORT COLLINS, Colo., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that Michael K
- 5y agoSTABStatera Biopharma, Inc. to Participate in the Benzinga Healthcare Small Cap ConferencePR NewswireFORT COLLINS, Colo., Sept. 22, 2021 /PRNewswire/ -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, will participate in the Benzinga
- 5y agoSTABStatera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare ConferencePR NewswireFORT COLLINS, Colo., Sept. 21, 2021 /PRNewswire/ -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, will participate in the 202
- 5y agoSTABStatera BioPharma, Inc. to Ring Nasdaq Stock Market Closing BellPR NewswireFORT COLLINS, Colo., Sept. 2, 2021 /PRNewswire/ -- Statera BioPharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that President and
- 5y agoSTABStatera BioPharma, Inc. to Ring Nasdaq Stock Market Closing BellPR NewswireFORT COLLINS, Colo., Sept. 2, 2021 /PRNewswire/ -- Statera BioPharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that President and
- 5y agoSTABStatera BioPharma, Inc. Provides Update on Integration of ImQuestPR NewswireFORT COLLINS, Colo., Sept. 1, 2021 /PRNewswire/ -- Statera BioPharma (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update on the integra
- 5y agoCBLISTABCytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."PR NewswireFORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corpora